Long term keratits treatment with topical cyclosporin a in autoimmune polyglandular syndrome type 1

• Published in: American journal of ophthalmology case reports Vol. 21; p. 101009
• Main Authors: AlAbbasi, Omar, Magliyah, Moustafa S., Ahad, Muhammad
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2021; Elsevier
• Subjects: APS1; Autoimmune keratitis; Autoimmune polyglandular syndrome; Case Report; Cyclosporin a; Autoimmune polyglandular syndrome; Autoimmune keratitis; APS1; Cyclosporin a
• ISSN: 2451-9936; 2451-9936
• DOI: 10.1016/j.ajoc.2020.101009

To report long term results of two cases treated with topical cyclosporin A 1% for keratitis associated with autoimmune polyglandular syndrome (APS1). A 25-year-old male and a 17-year-old female were referred from endocrinology as APS1-related autoimmune keratitis. Extended-duration treatment with topical cyclosporin A (CsA) 1% was used for 24 and 18 months, respectively. The first patient had improved best-corrected visual acuity (BCVA) from 20/200 and 20/300 in right and left eye to 20/60 in both eyes with markedly improved corneal opacification, while the second patient had improved BCVA from 20/400 and 20/300 in right and left eye to 20/160 in both eyes with persistent central stromal scarring in the right eye and discrete areas of stromal scarring in the left eye. Long-term topical CsA 1% offers a valuable option for treatment of APS1-related autoimmune keratitis.